Form 4: Cheryl Pegus Reports Changes in Beneficial Ownership of Boston Scientific Corp (BSX)

Director Cheryl Pegus reports acquisition of deferred stock units in Boston Scientific Corp.

Summary

• Cheryl Pegus, a director of Boston Scientific Corp (BSX), filed a Form 4 on May 9, 2025, reporting changes in beneficial ownership.
• On May 8, 2025, Pegus acquired 2,081 deferred stock units, representing the company's commitment to issue one share of Boston Scientific common stock per unit.
• These units were granted as an annual equity award and will vest in full upon the next annual meeting of stockholders.
• Vested shares will be issued following Pegus's separation from Board of Director service, according to the company's Non-Employee Director Deferred Compensation Plan.
• Pegus also acquired 605 deferred stock units in lieu of 50% yearly cash compensation.
• These units also vest in full upon the next annual meeting of stockholders and will be issued following separation from service.
• The price of the deferred stock units was $0.0000.
• Following these transactions, Pegus beneficially owns 5,893 deferred stock units.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction related to director compensation, indicating a stable and expected corporate governance practice. There are no indications of negative sentiment.

Positives

• The acquisition of deferred stock units aligns the director's interests with those of the shareholders.
• The equity award and compensation structure incentivize long-term commitment to the company.

Future Outlook

The deferred stock units will vest in full upon the next annual meeting of stockholders and will be issued following the reporting person's separation from Board of Director service.

Industry Context

Director compensation in the form of stock and deferred stock units is a common practice in publicly traded companies to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Companies like Medtronic (MDT) and Abbott Laboratories (ABT) also utilize equity-based compensation for their board members.
• The specific amounts and vesting schedules can vary based on company size, performance, and industry benchmarks.
• Deferred stock units are a common tool to provide long-term incentives and retain directors.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by aligning director interests with long-term company performance.
• The compensation structure impacts the director by providing equity-based incentives.

Next Steps

• The deferred stock units will vest upon the next annual meeting of stockholders.
• Vested shares will be issued following the reporting person's separation from Board of Director service.

Key Dates

Keywords

Form 4, beneficial ownership, deferred stock units, Boston Scientific, BSX, director compensation, equity award, Cheryl Pegus